



14 August 2023

RESPIRI COMPLETES ACQUISITION OF ACCESS MANAGED SERVICES LLC

Respiri Limited (ASX:RSH; OTCQB:RSHUF) (“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory remote patient monitoring, is pleased to announce the successful acquisition of Access Managed Services LLC (Access) by way of a Sale and Purchase Agreement.

Respiri entered into a binding Member Interest Purchase Agreement to acquire Access for up to US\$3.0 Million (~A\$4.5 million) with the first tranche payment of US\$1.25M completed.

The Access acquisition follows the successful SPP Offer (refer announcement 8 August 2023) and private placement (refer announcement 11 August 2023) with such funds used for the Tranche 1 payment and also to inject working capital ensuring a number of significant private payer business development opportunities pursued by Access continue to progress, and that operational plans around accelerating patient onboarding with existing clients remain on track.

The acquisition of Access increases:

- Respiri Remote Patient Monitoring (RPM) per patient monthly recurring revenues from US\$10-\$20 to US\$70-\$100 per user.
- The total addressable US market for Respiri from 50 Million respiratory patients to approximately 150 Million respiratory, cardiovascular, diabetes and obesity patients and introduces significant customer synergies and increased customer revenue opportunities.
- RPM monthly revenues resulting in patient numbers required to achieve breakeven going from 30K to 9K, which the company forecasts to achieve in CY2024.

The Respiri/Access collaboration has secured numerous RPM clients and also identified and progressed a number of immediate term significant potential payer contracts where Access have used wheezo® as a differentiated respiratory RPM device, expanded their offering to provide a full RPM service across all major disease states including cardiovascular, diabetes and obesity using other freely available medical devices.

Respiri also continue to develop wheezo® marketing/sales agreements with other US medical services companies with established patient services provided to healthcare organisation customers, to continue to expand the Company’s wheezo® RPM commercial footprint across the USA.

-ENDS-

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited

Mr Nicholas Smedley
Executive Chairman
Respiri Limited

P: +61 408 462 873
E: marjan@respiri.co

P: +61 447 074 160
E: nicholas@respiri.co

This ASX announcement has been authorised for release by the Board of Directors of Respiri Limited.

About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respiri's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo® is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Australia.

For additional information about Respiri and its products, please visit www.respiri.co

About wheezo®

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo®, follow the online link <https://wheezo.com>

wheezo® is a registered trademark of Respiri Limited.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.